FDA Grants Fast Track to Sangamo Pain Drug; Eli Lilly Acquires Assets
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Company and PTC Therapeutics closed asset sale transactions from Sangamo Therapeutics, generating $163.55 million in gross cash proceeds. Separately, the U.S. Food and Drug Administration granted Fast Track designation to Sangamo’s ST-503 program, which is being studied for chronic neuropathic pain.
From manilatimes.net
Why it matters
The Fast Track designation for ST-503, a clinical-stage investigational epigenetic regulator, suggests potential acceleration in its drug development process. The asset acquisition by Eli Lilly and Company strengthens its research and development capabilities.
From manilatimes.net
Who's involved
- FDARegulatory agency that granted Fast Track designation to the drug program
- Eli Lilly and CompanyAcquired assets from Sangamo Therapeutics in a transaction generating $163.55 million
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
- FDA
-
Eli Lilly and Company
American pharmaceutical company